Premature Ovarian Insufficiency
Obstetrics & Gynaecology · Reproductive Medicine · lean revision notes
Premature Ovarian Insufficiency
Premature ovarian insufficiency (POI) is the loss of normal ovarian function before the age of 40 years, presenting with menstrual disturbance, hypoestrogenism, and elevated gonadotrophins. It is a high-yield endocrinology-meets-gynaecology topic where the FSH > 25 IU/L cut-off and Turner syndrome as the commonest chromosomal cause are repeatedly examined.
High-yield: POI is not the same as premature menopause. POI is a spectrum with intermittent, unpredictable ovarian activity — up to 5–10% of women may still conceive spontaneously. "Insufficiency" was deliberately chosen over "failure" to reflect this fluctuating, incomplete nature.
Definition & terminology
POI (also called primary ovarian insufficiency) is defined by the triad:
- Amenorrhoea or oligomenorrhoea for ≥ 4 months in a woman younger than 40 years.
- Two serum FSH measurements > 25 IU/L (ESHRE 2016 threshold), taken at least 4 weeks apart.
- Associated hypoestrogenism (low serum oestradiol).
High-yield (most-tested fact): The diagnostic FSH cut-off per ESHRE 2016 guidelines is > 25 IU/L on two occasions ≥ 4 weeks apart. Older texts/ASRM may quote menopausal-range FSH > 40 IU/L — if a question gives both, the ESHRE 25 IU/L value is the currently preferred answer.
Distinguishing the terms
| Term | Age | Ovarian function | Fertility |
|---|---|---|---|
| Premature ovarian insufficiency | < 40 yr | Intermittent / fluctuating | 5–10% spontaneous conception possible |
| Premature/early menopause | < 40 yr (premature), 40–45 (early) | Permanently ceased | None |
| Diminished ovarian reserve | Any | Reduced quantity, normal cycles | Reduced but present |
| Physiological menopause | ~51 yr (median, India ~46–48) | Ceased | None |
Epidemiology: POI affects ~1% of women < 40 yr, ~0.1% < 30 yr, and ~0.01% < 20 yr.
Etiology & classification
The single most important exam concept is the cause list, grouped by mechanism. A large proportion (up to 50–90% in some series) remain idiopathic.
1. Chromosomal / genetic
- Turner syndrome (45,X) — the commonest chromosomal/karyotypic cause of POI. Accelerated follicular atresia leads to streak gonads. Mosaic forms (45,X/46,XX) may menstruate before failing.
- Fragile X premutation (FMR1, 55–200 CGG repeats) — the commonest single-gene cause; ~20% of premutation carriers develop POI (termed FXPOI). Always screen because of risk of fragile-X-affected offspring and FXTAS in relatives.
- Other: 46,XX gonadal dysgenesis, 46,XY (Swyer) gonadal dysgenesis, trisomy X, deletions of Xq (POF1/POF2 critical regions), galactosaemia (GALT mutation — galactose toxic to oocytes), BPES (FOXL2), autoimmune regulator defects.
2. Autoimmune (~5–30%)
- Autoimmune oophoritis — lymphocytic infiltration of theca cells; associated with anti-adrenal / anti-21-hydroxylase antibodies (the best-validated marker, linked to Addison disease).
- Part of Autoimmune Polyglandular Syndromes:
- APS type 1 (AIRE gene) — Addison + hypoparathyroidism + mucocutaneous candidiasis.
- APS type 2 (Schmidt) — Addison + autoimmune thyroid + type 1 diabetes.
- Associations: Hashimoto thyroiditis (commonest associated autoimmune disorder), Addison disease, type 1 diabetes, vitiligo, myasthenia, pernicious anaemia.
3. Iatrogenic / toxic
- Chemotherapy — alkylating agents (cyclophosphamide) are the most gonadotoxic; risk rises with cumulative dose and age.
- Pelvic radiotherapy — ovarian dose of ~2 Gy destroys ~50% of follicles (LD50); > 6 Gy usually causes permanent failure in adults.
- Bilateral oophorectomy / ovarian surgery (e.g. endometrioma cystectomy reduces reserve).
- Infections: mumps oophoritis, TB, CMV, malaria.
- Smoking (toxins accelerate atresia), galactose-rich states.
4. Enzymatic / metabolic
- 17α-hydroxylase deficiency (CYP17) — POI with hypertension and hypokalaemia.
- Galactosaemia, aromatase deficiency.
High-yield: Two facts dominate MCQs — (1) Turner syndrome = commonest chromosomal cause; (2) Fragile X premutation = commonest single-gene/heritable cause. Karyotype + FMR1 testing are mandatory in any woman with POI under ~30–35 yr.
Pathophysiology
Two broad mechanisms reduce the functional follicular pool below the threshold needed for cyclic activity:
- Follicle depletion — too few germ cells at birth (gonadal dysgenesis) or accelerated atresia (Turner, chemo/radiation, galactosaemia).
- Follicle dysfunction — adequate follicles that cannot respond: autoimmune destruction of theca, FSH/LH receptor mutations (resistant ovary / Savage syndrome), or signalling/enzyme defects.
The end result is falling inhibin B and anti-Müllerian hormone (AMH) from the granulosa, loss of negative feedback, and a compensatory rise in FSH (then LH) — a hypergonadotrophic hypogonadism. Oestradiol falls, producing vasomotor and atrophic symptoms.
Mechanistic flow:
Follicle loss/dysfunction → ↓ inhibin B & AMH → loss of negative feedback at pituitary → ↑ FSH (> 25 IU/L) → ↓ oestradiol → amenorrhoea + hypoestrogenic symptoms
Clinical features
POI may present as primary amenorrhoea (especially Turner / gonadal dysgenesis — failure to menstruate by 15 yr) or, more often, secondary amenorrhoea / oligomenorrhoea after previously normal cycles.
- Menstrual: irregular cycles, skipped periods, then amenorrhoea (may be intermittent).
- Hypoestrogenic / menopausal: hot flushes, night sweats, vaginal dryness, dyspareunia, reduced libido, sleep disturbance, mood changes/depression, poor concentration.
- Reduced fertility / subfertility — often the presenting complaint.
- Syndromic clues: short stature, webbed neck, cubitus valgus, widely spaced nipples, coarctation, lymphoedema → Turner; hyperpigmentation, fatigue, hypotension, salt craving → Addison/autoimmune; intellectual disability or tremor-ataxia in male relatives → fragile X.
High-yield: Many young POI patients lack florid hot flushes because residual ovarian activity fluctuates. Do not exclude POI just because the patient is asymptomatic between menses — confirm biochemically.
Diagnosis & investigation of choice
A structured workup confirms the diagnosis and identifies a cause.
Stepwise approach
- Exclude pregnancy — β-hCG first in any amenorrhoea.
- Serum FSH — repeat after ≥ 4 weeks; two values > 25 IU/L confirm POI. Pair with serum oestradiol (low).
- Serum AMH — markedly low; supports diminished reserve (not diagnostic alone but useful and high-yield as a reserve marker).
- Prolactin and TSH — exclude hyperprolactinaemia / thyroid disease as mimics.
- Karyotype — mandatory, especially < 30 yr → detect Turner / Y-chromosome material.
- FMR1 (fragile X) premutation testing — for genetic counselling.
- Autoimmune screen — anti-21-hydroxylase (adrenal) antibodies (best validated), anti-thyroid peroxidase antibodies, plus fasting glucose; screen for Addison/thyroid disease.
- Pelvic ultrasound — small ovaries, reduced antral follicle count.
- Baseline DEXA bone densitometry — assess osteoporosis risk at diagnosis.
High-yield: The investigation of choice to confirm POI is serum FSH (> 25 IU/L on two occasions ≥ 4 weeks apart). Karyotype is the key test to find the commonest chromosomal cause; FMR1 for the commonest single-gene cause. Anti-21-hydroxylase antibody is the best autoimmune marker.
| Hormone | Pattern in POI |
|---|---|
| FSH | High (> 25 IU/L), repeated |
| LH | High |
| Oestradiol | Low |
| AMH | Very low / undetectable |
| Inhibin B | Low |
| Prolactin / TSH | Normal (to exclude mimics) |
Crucial pitfall: If Y-chromosome material is found on karyotype (e.g. 45,X/46,XY mosaicism, Swyer syndrome), the dysgenetic gonads carry a high risk of gonadoblastoma/dysgerminoma → bilateral gonadectomy is indicated.
Management
There is no proven treatment to restore fertility or reverse ovarian function. Management targets symptom control, long-term hormone replacement to protect bone and cardiovascular health, fertility counselling, and psychological support.
1. Hormone replacement therapy (HRT) — cornerstone
High-yield: Unlike postmenopausal women (where HRT is selective), in POI HRT is recommended for essentially all women until at least the natural age of menopause (~50–51 yr) to prevent osteoporosis and cardiovascular disease — the benefits clearly outweigh risks at this young age.
- Oestrogen (oral or, preferably, transdermal 17β-oestradiol — more physiological, lower VTE risk) plus a progestogen if the uterus is present (to prevent endometrial hyperplasia).
- Doses are higher than standard postmenopausal HRT because young women need physiological replacement (e.g. transdermal oestradiol 100 µg).
- Combined oral contraceptive pills (COCPs) are an acceptable alternative, often preferred by younger women (especially those who want contraception, since spontaneous ovulation can still occur) — but HRT gives better bone protection.
- HRT in POI does not carry the same breast-cancer/CV risk profile as in older postmenopausal women; it merely restores what age-matched peers naturally have.
2. Fertility management
- Spontaneous pregnancy occurs in ~5–10%; no reliable way to induce it. Ovulation-induction success is poor.
- Oocyte / embryo donation with IVF is the most effective and treatment of choice for fertility in established POI.
- Fertility preservation before gonadotoxic therapy: oocyte/embryo cryopreservation, ovarian tissue cryopreservation, GnRH agonist co-treatment during chemotherapy (debated).
- Counsel about contraception if pregnancy is not desired — residual ovulation can occur.
3. Bone health
- Baseline DEXA, ensure adequate calcium and vitamin D, weight-bearing exercise, smoking cessation.
- Long-term oestrogen replacement is the principal protection against accelerated osteoporosis.
4. Cardiovascular & general
- Monitor lipids, blood pressure, weight; oestrogen replacement reduces premature cardiovascular and possibly neurocognitive risk.
5. Treat the cause / associations
- Treat associated hypothyroidism / Addison disease; counsel and surveil for autoimmune disorders.
- Gonadectomy if Y-chromosome material present.
- Psychological support — diagnosis carries grief over fertility/identity; address mood and offer counselling.
Complications
- Osteoporosis & fragility fractures — from prolonged hypoestrogenism (years longer than normal menopause).
- Premature cardiovascular disease — endothelial dysfunction, dyslipidaemia, higher mortality if untreated.
- Infertility / subfertility — major psychosocial impact.
- Genitourinary syndrome — vaginal atrophy, dyspareunia, recurrent UTIs.
- Mood disorders & cognitive effects — depression, anxiety; possible long-term cognitive risk.
- Gonadal malignancy — gonadoblastoma/dysgerminoma in dysgenetic gonads with Y material.
- Associated autoimmune disease — adrenal insufficiency (potentially life-threatening) and thyroid disease.
Key differentials
| Condition | Distinguishing feature |
|---|---|
| Pregnancy | β-hCG positive |
| Hypothalamic amenorrhoea (stress, weight loss, exercise) | Low FSH/LH (hypogonadotrophic), low oestradiol |
| Hyperprolactinaemia | High prolactin, galactorrhoea; FSH not elevated |
| PCOS | Oligomenorrhoea + hyperandrogenism, normal/raised LH:FSH, normal-high AMH |
| Thyroid dysfunction | Abnormal TSH |
| Asherman syndrome | Normal hormones, history of uterine instrumentation; absent withdrawal bleed |
| Outflow obstruction (imperforate hymen) | Primary amenorrhoea with cyclical pain, normal hormones |
| Physiological menopause | Age > 40 yr |
High-yield: The pivotal split is hypergonadotrophic (high FSH = POI, ovarian problem) vs hypogonadotrophic (low FSH = hypothalamic/pituitary problem). This FSH direction is a favourite single-line MCQ discriminator.
Mnemonics & named entities
- Causes of POI — "FIGAROO": Fragile X, Iatrogenic (chemo/radiation/surgery), Galactosaemia, Autoimmune, Radiation, Ovarian dysgenesis (Turner), Other/idiopathic.
- Savage syndrome = resistant ovary syndrome (FSH receptor insensitivity; follicles present but unresponsive).
- Swyer syndrome = 46,XY pure gonadal dysgenesis (streak gonads, phenotypic female, needs gonadectomy).
- Schmidt syndrome = APS-2 (Addison + thyroid ± T1DM) — think POI + adrenal/thyroid.
- FXPOI / FXTAS = fragile-X-associated POI / tremor-ataxia syndrome (premutation spectrum).
Recently asked / exam angle
- FSH diagnostic threshold: "Diagnostic FSH level for POI?" → > 25 IU/L on two occasions ≥ 4 weeks apart (ESHRE). Watch for the distractor > 40 IU/L.
- Commonest chromosomal cause of POI → Turner syndrome (45,X).
- Commonest single-gene/heritable cause → Fragile X (FMR1) premutation.
- Best autoimmune marker / association → anti-21-hydroxylase (adrenal) antibody; Hashimoto thyroiditis is the commonest associated autoimmune disease.
- Best fertility option in established POI → donor oocyte IVF.
- HRT in POI vs postmenopausal HRT → continue until ~50 yr; benefits outweigh risks; transdermal oestradiol preferred.
- Most gonadotoxic chemotherapy → alkylating agents (cyclophosphamide).
- Ovarian radiation LD50 → ~2 Gy destroys half the follicles.
- Y-chromosome on karyotype → risk of gonadoblastoma → gonadectomy.
- Differential by FSH direction (hyper- vs hypogonadotrophic) is a recurring reasoning item.
Rapid revision
- POI = ovarian dysfunction before 40 yr + amenorrhoea/oligomenorrhoea ≥ 4 months + FSH > 25 IU/L ×2 (≥4 wk apart) + low oestradiol.
- It is hypergonadotrophic hypogonadism (high FSH/LH, low oestradiol, low AMH/inhibin B).
- Turner syndrome (45,X) = commonest chromosomal cause; fragile X premutation = commonest single-gene cause.
- Most cases overall are idiopathic; autoimmune oophoritis is a key reversible-association group.
- Anti-21-hydroxylase antibody is the best autoimmune marker; screen for Addison & thyroid disease.
- Mandatory workup: β-hCG, FSH ×2, oestradiol, AMH, prolactin, TSH, karyotype, FMR1, autoantibodies, pelvic USG, DEXA.
- HRT is for almost all POI women until ~50 yr (transdermal oestradiol + progestogen if uterus present) to protect bone & heart.
- Donor-oocyte IVF is the most effective fertility treatment; ~5–10% conceive spontaneously, so counsel on contraception too.
- Alkylating agents are most gonadotoxic; ovarian radiation ~2 Gy kills 50% of follicles.
- Y-chromosome material → gonadectomy (gonadoblastoma/dysgerminoma risk).
- Key complications: osteoporosis, premature cardiovascular disease, infertility, mood disorders.
- Differentiate from hypothalamic amenorrhoea (low FSH) and PCOS (high AMH, hyperandrogenism) — FSH direction is the discriminator.